Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Related Citations for PubMed (Select 24576318)

1.

Clinical utility of urinary soluble Fas in screening for bladder cancer.

Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Bhatt ML.

Asia Pac J Clin Oncol. 2014 Feb 27. doi: 10.1111/ajco.12165. [Epub ahead of print]

PMID:
24576318
2.

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF.

Cancer. 2006 Apr 15;106(8):1701-7.

3.

Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder.

Srivastava AK, Singh PK, Rath SK, Dalela D, Goel MM, Bhatt ML.

Tumour Biol. 2014 Nov;35(11):11435-42. doi: 10.1007/s13277-014-2474-z. Epub 2014 Aug 15.

PMID:
25123267
4.

Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder.

Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Goel MM, Bhatt ML.

Tumour Biol. 2014 Aug;35(8):8243-8. doi: 10.1007/s13277-014-2026-6. Epub 2014 May 23.

PMID:
24852426
5.

Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.

Gilbert SM, Veltri RW, Sawczuk A, Shabsigh A, Knowles DR, Bright S, O'Dowd GJ, Olsson CA, Benson MC, Sawczuk IS.

Urology. 2003 Mar;61(3):539-43.

PMID:
12639642
6.

Diagnostic role of survivin in urinary bladder cancer.

Srivastava AK, Singh PK, Srivastava K, Singh D, Dalela D, Rath SK, Goel MM, Brahma Bhatt ML.

Asian Pac J Cancer Prev. 2013;14(1):81-5.

7.

Prognostic significance of soluble Fas in the serum of patients with bladder cancer.

Mizutani Y, Yoshida O, Bonavida B.

J Urol. 1998 Aug;160(2):571-6.

PMID:
9679930
8.
9.

Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.

May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, Nowack R, Siegsmund M, Hoschke B.

Urology. 2007 Sep;70(3):449-53. Epub 2007 Aug 3.

PMID:
17688921
10.

Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study.

Yang H, Li H, Wang Z, Gao J, Guo Y.

Urol Int. 2013;91(4):456-61. doi: 10.1159/000350752. Epub 2013 Aug 14.

PMID:
23948854
11.
12.

Diagnostic value of urinary molecular markers in bladder cancer.

Eissa S, Swellam M, el-Mosallamy H, Mourad MS, Hamdy N, Kamel K, Zaglol AS, Khafagy MM, el-Ahmady O.

Anticancer Res. 2003 Sep-Oct;23(5b):4347-55.

PMID:
14666650
13.

Possible role of telomerase and sFas in pathogenesis of various bladder lesions associated with schistosomiasis.

Shaker OG, Hammam O, Salehd A, el-Leithy T, Wishahi M.

Clin Biochem. 2009 Jun;42(9):864-72. doi: 10.1016/j.clinbiochem.2008.12.025. Epub 2009 Jan 14.

PMID:
19272297
14.

Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.

Kundal VK, Pandith AA, Hamid A, Shah A, Kundal R, Wani SM.

Asian Pac J Cancer Prev. 2010;11(5):1279-82.

15.

Voided urinary cytology in bladder cancer: is it time to review the indications?

Talwar R, Sinha T, Karan SC, Doddamani D, Sandhu A, Sethi GS, Srivastava A, Narang V, Agarwal A, Adhlakha N.

Urology. 2007 Aug;70(2):267-71.

PMID:
17826487
16.

Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.

Shariat SF, Matsumoto K, Casella R, Jian W, Lerner SP.

Eur Urol. 2005 Jul;48(1):69-76. Epub 2005 Mar 8.

PMID:
15967254
17.

[Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].

Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.

Arch Esp Urol. 2002 Jan-Feb;55(1):41-9. Spanish.

PMID:
11957750
18.

[Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].

Pu XY, Wang ZP, Chen YR, Wu YL, Wang HP, Wang XH.

Ai Zheng. 2008 Sep;27(9):970-3. Chinese.

PMID:
18799038
19.

Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.

Passerotti CC, Srougi M, Bomfim AC, Martins JR, Leite KR, Dos Reis ST, Sampaio LO, Ortiz V, Dietrich CP, Nader HB.

Urol Oncol. 2011 Nov-Dec;29(6):710-5. doi: 10.1016/j.urolonc.2009.10.006. Epub 2009 Dec 4.

PMID:
19962919
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk